Compare PRTS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTS | LUNG |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 57.9M |
| IPO Year | 2006 | 2020 |
| Metric | PRTS | LUNG |
|---|---|---|
| Price | $5.37 | $1.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $0.50 | ★ $5.38 |
| AVG Volume (30 Days) | 16.1K | ★ 251.1K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,497,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $5.25 | $18.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $0.37 | $1.13 |
| 52 Week High | $7.27 | $3.39 |
| Indicator | PRTS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 36.66 |
| Support Level | $0.53 | N/A |
| Resistance Level | $6.61 | $1.65 |
| Average True Range (ATR) | 0.40 | 0.09 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 41.05 | 2.30 |
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. Its products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.